الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 107 |  |  |
| | | from | 107 | | |
Abstract
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed.
Aim and objectives
To compare the role of colchicine as a potential therapeutic option in COVID – 19 confirmed cases in addition to the standard of care versus the standard of care alone.
This retrospective cohort study was conducted on 100 positive nasopharyngeal swabs PCR for SARS- CoV-2 viral infection who were admitted to Ain Shams Field Hospital. (50 in each):
• group A: includes patients who received colchicine (An initial dose of 1.5 mg orally on the first day, followed by 0.5 mg every 12 hours on days 2 to 7 and continuing with 0.5 mg a day until completing 14 days). plus standard treatment (hydroxychloroquine 400 ml /12 hr orally loading dose on the first day then 200ml/12 hr orally for 5 or 10 days plus Azithromycine 500ml/24 hr orally for 5 days).
• group B: includes patients who received standard of care (hydroxychloroquine 400 ml /12 hr orally loading dose on the first day then 200ml/12 hr orally for 5 or 10 days plus Azithromycine 500ml/24 hr orally for 5 days).
There was no statistical significant difference between the two studied groups concerning SpO2 at the start of hospital admission or at the end of hospital stay (p>0.05). On the other hands, there was highly significant improvement in SpO2 at the end of hospital stay compared to SpO2 at the start of hospital admission in both group A & B (P<0.001).
In patient receiving Colchicine, 4 patients experienced mild GIT symptoms that were relieved by symptomatic treatment. No recorded serious side effects that necessitated stop of treatment
Time of constitutional symptoms resolution as fever, bony aches and sore throat was significantly lower in group A compared to group B (p<0.001).
group A showed significant decrease in duration of hospital stay compared to group B (p< 0.001).
Regarding to signs of secondary bacterial infection or discharge on Domiciliary oxygen, there was no statistically significant difference between the two studied groups (P>0.05).
Need for ICU admission was significantly lower in group A compared to group B (p= 0.013). Also, need for invasive mechanical ventilation was significantly lower in group A compared to group B (p= 0.025).
Concerning outcome Mortality rate was statistically lowered in group A (P= 0.006)
In group A there were 9 patients suffering gouty arthritis and FMF, these patients were on long-term colchicine treatment. These patients exhibited statistically significant shorter time for constitutional symptoms resolution, shorter duration of hospital stay, higher SpO2 upon admission and at the end of hospital stay, compared to other patients in group A.